Trident Texofab Limited announced the outcome of its Board Meeting held on August 10, 2026. The board approved the un-audited financial results for the quarter ended June 30, 2026. Additionally, the company noted the resignation of its statutory auditors, M/s. Shah Kailash and Associates LLP, and proceeded to appoint M/s. Prit Agrawal & Co. as the new internal auditor for the financial year 2026-27.
Trident Texofab Board Meeting Highlights
On August 10, 2026, Trident Texofab Limited’s Board of Directors convened to discuss and approve key financial and operational matters. The meeting resulted in the approval of the un-audited financial results for the quarter ended June 30, 2026. These results, along with the Limited Review Report, have been formally taken on record by the Board. An extract of these results will be published in newspapers and made available on the company’s website.
Auditor Resignation and Appointment
The Board also acknowledged the resignation of M/s. Shah Kailash and Associates LLP as the Statutory Auditor, effective August 10, 2026. The reason cited for the resignation includes the firm’s increasing professional commitments and workload. The Audit Committee and the Board will consider the appointment of a new statutory auditor in due course to fill the resulting casual vacancy. In related business, the Board approved the appointment of M/s. Prit Agrawal & Co. as the Internal Auditor for the financial year 2026-27.
Financial Performance Overview (Q1 FY27)
The unaudited financial results for the quarter ended June 30, 2026, show a Profit/(Loss) of ₹52.18 Lakhs from continuing operations. The total comprehensive income for the period stood at ₹52.18 Lakhs. Basic and diluted earnings per share were ₹0.35.
Other Business
The Board also took note of various compliances made during the quarter ended June 30, 2026.
Source: BSE
